Optimizing the Clinical Application of CAR T-Cell Therapy: Best Practices for the Community Setting

Interact with peers while gaining expert insight on how to best use CAR T-cells in the treatment of lymphomas and leukemias in this interactive, case-based 1-hour live meeting. The latest clinical data will be highlighted, as well as expert treatment options from CCO’s online CAR T-cell toxicity management tool. After the meeting, download the associated slideset for use in your clinic.

Register Now!


  • The scientific principles underlying the use of CAR T-cells
  • Incorporating recent data from clinical trials of currently approved and emerging CAR T-cells in R/R lymphomas and leukemias
  • Managing toxicities associated with CAR T-cell therapies
  • Identifying and understanding the challenges that may hinder community oncologists’ use of and referral to CAR T-cell therapy
  • Key data from clinical trials of emerging CAR T-cell therapies for the treatment of lymphomas and leukemias


Date / Time
Event Details


Michael R. Bishop, MD

Professor of Medicine
, Hematopoietic Stem Cell Transplantation Program
University of Chicago
Chicago, Illinois

Caron A. Jacobson, MD

Medical Director, Immune Effector Cell Therapy Program
Assistant Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Jae H. Park, MD

Assistant Member
Leukemia Service and Cellular Therapeutics Center
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve participants’ competence and performance in applying evolving clinical evidence and expert guidance to best use CAR T-cells in the treatment of lymphomas and leukemias.

Target Audience
This program is intended for hematologists/oncologists, advanced practice registered nurses, nurses, pharmacists, and other healthcare professionals who treat and manage refractory and relapsed lymphomas and leukemias.

Learning Objectives

  • Recall the scientific principles underlying the use of CAR T-cells
  • Integrate recent developments, clinical trial findings, and indications of recently approved and emerging CAR T-cell therapies into clinical practice to enhance clinical outcomes
  • Determine best practices for timely referral and having proper channels of communication between community and academic centers to streamline the logistics of delivering therapy
  • Apply multidisciplinary interventions to identify and manage acute toxicities and ensure patient safety while receiving CAR T-cell therapy


Joint Accreditation Statement

In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.

Pharmacist Continuing Education

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008162-0000-19-890-L01-P

Type of Activity 

Pharmacists have up to 30 days to complete the online evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Disclosure of Conflicts of Interest 
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.